Johnson & Johnson Preps For Q3 Earnings As MedTech Expands, But Stock Sends Mixed Signals
Portfolio Pulse from Surbhi Jain
Johnson & Johnson is set to announce its Q3 earnings, with Wall Street expecting an EPS of $2.21 and revenue of $22.16 billion. The company recently acquired V-Wave to expand its MedTech portfolio, but this will dilute EPS in the short term. Meanwhile, a drug trial was halted, affecting its stock performance. The stock shows mixed technical signals, with potential downward pressure.
October 14, 2024 | 2:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Johnson & Johnson is preparing for its Q3 earnings report, with expectations of $2.21 EPS and $22.16 billion in revenue. The recent acquisition of V-Wave will impact short-term EPS negatively, while a halted drug trial adds uncertainty. The stock shows mixed technical signals, indicating potential short-term downward pressure.
The upcoming earnings report is crucial for JNJ, with expected EPS and revenue figures setting the stage. The recent acquisition in MedTech is a strategic move but will dilute EPS in the short term, which is a negative factor. The halted drug trial adds to the uncertainty. Technical indicators like MACD and RSI suggest potential downward pressure, making the short-term outlook bearish.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100